TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tarsus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$69.50+1.43 (+2.10%)
Close on Oct 19, 2026
- Market cap
- $3.02B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
-15.7%
Net margin
-14.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +146.7% | +159.5% | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -33.5% | -23.4% | |
| Return on assets | – | -23.3% | -14.1% | |
| Current ratio | – | 31.68 | 3.85 | |
| Debt to equity | – | – | 0.21 | |
| Interest coverage | – | – | -7.9× | |
| Capex to revenue | – | – | 2.2% | |
| Diluted shares | – | 6M | 42M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Tarsus Pharmaceuticals generated $265.75M from operations and spent $14.02M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$265.75M
Used
$14.02M
Capital expenditure$14.02M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-14.7%
×Asset turnover0.96×
×Equity multiplier1.65×
=Return on equity, FY2025-23.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -14.7% | 0.96× | 1.65× | -23.4% |
| FY2024 | -63.2% | 0.57× | 1.52× | -54.8% |
| FY2023 | -778.9% | 0.07× | 1.27× | -69.7% |
| FY2022 | -240.5% | 0.13× | 1.13× | -34.5% |
| FY2021 | -24.2% | 0.33× | 1.05× | -8.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$66.42M
- Cash generatingOperating cash flow above zero-$12.45M
- Return on assets improvedROA up on the prior year-43.5% → -17.6%
- Earnings backed by cashOperating cash flow above net income-$12.45M vs -$66.42M
- Less leverageLong-term debt to assets fell19.1% → 12.9%
- Better liquidityCurrent ratio rose4.42 → 3.85
- No dilutionShare count did not rise38M → 42M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.69 → 1.20